Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Sell at Wall Street Zen

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Oramed Pharmaceuticals Price Performance

Oramed Pharmaceuticals stock traded up $0.04 during midday trading on Friday, hitting $2.15. 36,803 shares of the stock were exchanged, compared to its average volume of 153,036. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.09. The firm has a market cap of $87.83 million, a P/E ratio of 19.55 and a beta of 1.65. The company has a 50 day moving average price of $2.22 and a two-hundred day moving average price of $2.30.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.16). The company had revenue of $2.00 million for the quarter. As a group, analysts predict that Oramed Pharmaceuticals will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BML Capital Management LLC increased its position in shares of Oramed Pharmaceuticals by 14.3% in the 1st quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock worth $6,464,000 after purchasing an additional 376,841 shares during the last quarter. Boothbay Fund Management LLC increased its position in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock worth $2,045,000 after purchasing an additional 16,857 shares during the last quarter. Peapod Lane Capital LLC increased its position in shares of Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock worth $540,000 after purchasing an additional 24,985 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 70,190 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 17,510 shares during the last quarter. Institutional investors own 12.73% of the company's stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.